Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 50.0% in December

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 383,700 shares, a growth of 50.0% from the November 30th total of 255,800 shares. Approximately 9.7% of the shares of the company are short sold. Based on an average daily volume of 449,900 shares, the days-to-cover ratio is currently 0.9 days.

Allarity Therapeutics Stock Performance

Shares of NASDAQ:ALLR remained flat at $1.08 on Friday. 854,832 shares of the company’s stock were exchanged, compared to its average volume of 277,357. The business has a fifty day simple moving average of $1.24 and a 200-day simple moving average of $3.78. Allarity Therapeutics has a 52 week low of $0.90 and a 52 week high of $336.00.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.